ACTRN12624000274572招募中Unknown
A multi-center, prospective, longitudinal cohort study of Chlamydia trachomatis infection and reinfection in adults aged 18 to 29 years.
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 29 Years（—）
- 性别
- All
入选标准
- •1. Aged 18 to 29 years on the day of inclusion
- •2 .New sex partner within the past 6 months, or more than one current sex partner, or partner with known sexually transmitted infection (STI), or inconsistent condom use.
- •3. For persons living with human immunodeficiency virus (HIV): participant with a stable HIV infection determined by a CD4 count greater than 200/mm3, and currently on antiretrovirals for at least 6 months
- •4. A female participant is eligible to participate if she is not pregnant. A female participant of childbearing potential must have a negative highly sensitive urine pregnancy test at the enrollment visit (V01).
- •5. Informed consent form has been signed and dated.
- •6. Able to attend all scheduled visits and to comply with all study procedures
排除标准
- •1. Known or suspected congenital immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
- •2. Unstable acute or chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion.
- •3. For female participants, is menstruating at the time of enrollment visit. Enrollment visit can be postponed until the menstruation period ends.
- •4. Genital or rectal douching from 48 hours before enrollment visit. Enrollment visit can be postponed until more than 48 hours have passed after the last genital or rectal douching.
- •5. Documented hysterectomy
- •6. Receipt of immune globulins, blood or blood-derived products in the past 3 months
- •7. Receipt of oral or injectable prohibited antibiotic therapy within 21 days prior to enrollment visit (prohibited antibiotics include azithromycin, erythromycin, doxycycline, levofloxacin, ofloxacin, ceftriaxone, amoxicillin, ciprofloxacin, tetracycline, and cefixime).
- •Enrollment visit can be postponed until more than 21 days have passed after the last receipt of an antibiotic.
- •8. Participation at the time of study enrollment (or in the 3 months preceding the enrollment) or planned participation during the present study period in another clinical study investigating a vaccine, or a drug.
- •9. Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily.
- •10. Identified as an investigator or employee of the investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (ie, parent, spouse, natural or adopted child) of the investigator or employee with direct involvement in the proposed study
研究者
相似试验
进行中（未招募）
不适用
A Prospective, Multi-center, Longitudinal Cohort Study of Dermagraft® in Subjects with Venous Leg Ulcers: A Long-term Follow-up to the DEVO-Trial - Dermagraft® in Venous Leg Ulcers (DEVO Follow up)EUCTR2010-019887-35-DEAdvanced BioHealing Inc180
进行中（未招募）
1 期
A Prospective, Multi-center, Longitudinal Cohort Study of Dermagraft® in Subjects with Venous Leg Ulcers: A Long-term Follow-up to the DEVO-Trial - Dermagraft® in Venous Leg Ulcers (DEVO Follow up)Venous leg ulcersMedDRA version: 9.1 Level: LLT Classification code 10024134 Term: Leg ulcer (exc varicose)EUCTR2010-019887-35-GBAdvanced BioHealing Inc180
进行中（未招募）
不适用
A Prospective, Multi-center, Longitudinal Cohort Study of Dermagraft® in Subjects with Venous LegUlcers: A Long-term Follow-up to the DEVO-Trial - Dermagraft® in Venous Leg Ulcers (DEVO Follow up)Venous leg ulcersMedDRA version: 14.1Level: LLTClassification code 10024134Term: Leg ulcer (exc varicose)System Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2010-019887-35-EEShire Regenerative Medicine, Inc.180
已完成
4 期
VIRTUE - Study of Anti diabetes medicines during RAMADACTRI/2012/11/003109ovartis HealthCare private Limited1,000
招募中
4 期
A prospective and retrospective multicenter cohort study of Daclatasvir + Asunaprevir combination therapy for chronic hepatitis C with and without liver cirrhosisJPRN-UMIN000016769The University of Tokyo Hospital Department of Gastroenterology1,000